1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,720 | 0,845 | 22.11. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - REDEMPTIONS AND SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCTS | 1 | HKEx | ||
| Mo | IMMUNEONCO-B (01541): ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| Mo | IMMUNEONCO-B (01541): AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 07.11. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - INCREASE IN SHAREHOLDING BY EXECUTIVE DIRECTOR, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD | 2 | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 23.10. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATENT DOSED IN THE PHASE IB/II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM01 | - | HKEx | ||
| 16.10. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 16.10. | IMMUNEONCO-B (01541): COMPLETION OF PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 1 | HKEx | ||
| 09.10. | BRIEF: ImmuneOnco to raise $45 million via share placement at 13% discount | 2 | Bamboo Works | ||
| 09.10. | IMMUNEONCO-B (01541): PLACING OF NEW H SHARES UNDER GENERAL MANDATE | 2 | HKEx | ||
| 02.10. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM2510 | 2 | HKEx | ||
| 29.09. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPLICATION FOR THE PHASE III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF FOLLICULAR LYMPHOMA | - | HKEx | ||
| 23.09. | IMMUNEONCO-B (01541): 2025 INTERIM REPORT | 1 | HKEx | ||
| 26.08. | IMMUNEONCO-B (01541): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2025 | - | HKEx | ||
| 18.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE I CLINICAL TRIAL OF IMC-003/IMM72 | 3 | HKEx | ||
| 12.08. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | - | HKEx | ||
| 31.07. | Instil Bio: ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China | 158 | GlobeNewswire (Europe) | Partial responses observed in 80% of squamous NSCLC front-line patients and in 46% of non-squamous NSCLC front-line patients Safety profile supports further clinical development, with no dose-limiting... ► Artikel lesen | |
| 30.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - MILESTONE PAYMENT RECEIVED UNDER THE LICENSE AND COLLABORATION AGREEMENT WITH AXION BIO | - | HKEx | ||
| 11.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - UNUSUAL PRICE MOVEMENTS | 2 | HKEx | ||
| 02.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - CLEARANCE OF IND APPLICATION FOR IMM2510/AXN-2510 BY THE U.S. FDA | 1 | HKEx | ||
| 30.06. | IMMUNEONCO-B (01541): TERMS OF REFERENCE OF THE NOMINATION COMMITTEE | - | HKEx |
1 2 Weiter >>
29 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 70,56 | -0,13 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| NUVALENT | 105,88 | -1,97 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| QIAGEN | 40,380 | +2,38 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,170 | +8,45 % | Recursion (RXRX) Jumps 8% on Bargain-Hunting | ||
| BIONTECH | 83,05 | +0,06 % | Raus aus BioNTech? Rein in Evotec und Vidac Aktie? Was läuft da mit Johnson und Johnson? | Paukenschläge bei Biotechs: Partner Pfizer verkauft seine komplette Beteiligung am deutschen Biotech-Champion BioNTech. Sollten Anleger es genauso machen? Dagegen liefert Vidac Pharma mehr und mehr... ► Artikel lesen | |
| COGENT BIOSCIENCES | 36,770 | +5,97 % | COGT Stock Skyrockets 120% in a Month: Here's What You Need to Know | ||
| JANUX THERAPEUTICS | 28,800 | +0,73 % | Wolfe Research initiates Janux Therapeutics stock with Peerperform rating | ||
| PRAXIS PRECISION MEDICINES | 169,78 | +3,33 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines to Participate in Upcoming Fireside Chat | ||
| OLEMA PHARMACEUTICALS | 23,190 | +5,36 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 29,460 | +7,89 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| IMMUNOVANT | 22,580 | -0,92 % | Immunovant, Inc. - 8-K, Current Report | ||
| EVOTEC | 5,206 | +0,58 % | Evotec: Startet jetzt der Turnaround? | ||
| MINERALYS THERAPEUTICS | 42,000 | +0,33 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update | - Submission of New Drug Application (NDA) for lorundrostat planned for late-2025/Q1 2026 - - Completed enrollment in Explore-OSA trial; topline results anticipated in Q1 2026 - - Conference call... ► Artikel lesen | |
| RAPPORT THERAPEUTICS | 27,250 | +1,49 % | Rapport Therapeutics, Inc.: Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures | Trial met primary long episode endpoints with high statistical significance, and RAP-219 was generally well toleratedPatients achieved 77.8% reduction in clinical seizures (p=0.01), with 24% achieving... ► Artikel lesen | |
| IMMUNOME | 18,510 | +5,77 % | Varegacestat-Potenzial: Stephens erhöht Kursziel für Immunome auf 33 US-Dollar |
Das Unternehmen IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,040 (-5,23 %) liegt der Kurs bei 0,725 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.